INNOVATIVE BIOLOGICS, INC

Company Information

Company Name
INNOVATIVE BIOLOGICS, INC
Address
INNOVATIVE BIOLOGICS, INC
13455 SUNRISE VALLEY DR, STE 200
HERNDON, VA, 20171 3296
Phone
n/a
URL
n/a
DUNS
169174146
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$505,595.00
3
SBIR Phase II
$4,398,456.00
3

Award List

  1. SMALL MOLECULE BLOCKERS OF B. ANTHRACIS TOXIN

    Amount: $106,498.00

    DESCRIPTION (provided by applicant): The overall goal of this SBIR proposal is the identification of small molecules capable of blocking the cytotoxic action of Bacillus anthracis lethal toxin by blo ...

    SBIR Phase I 2002 Department of Health and Human Services
  2. Small Molecule Inhibitors of C. perfringens Epsilon-Toxin

    Amount: $99,097.00

    DESCRIPTION (provided by applicant): The overall goal of this SBIR Phase I proposal is to find compounds that inhibit C. perfringens epsilon-toxin action using a novel approach for the inactivation of ...

    SBIR Phase I 2007 Department of Health and Human Services
  3. Small Molecule Inhibitors of C. perfringens Epsilon-Toxin

    Amount: $741,493.00

    DESCRIPTION (provided by applicant): C. perfringens epsilon-toxin (ETX) is a potential biological weapon included in the list of category B priority agents. The overall goal of this proposal is to ide ...

    SBIR Phase II 2008 Department of Health and Human Services
  4. In vivo Testing of S. aureus alpha-Hemolysin Inhibitors

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): We have recently demonstrated that alpha-hemolysin produced by S. aureus plays a key role in the pathogenesis of staphylococcal pneumonia, and identified beta-cycl ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Small Molecule Blockers of B. anthracis Toxin

    Amount: $1,703,293.00

    DESCRIPTION (provided by investigator): Results from our SBIR Phase I project demonstrated that beta-cyclodextrin derivatives designed to block the trans-membrane channel formed by B. anthracis protec ...

    SBIR Phase II 2004 Department of Health and Human Services
  6. Small Molecule Blockers of B. anthracis Toxin

    Amount: $1,953,670.00

    DESCRIPTION (provided by applicant): The results from our SBIR Phase II project demonstrated that ?-cyclodextrin derivatives designed to block the transmembrane channel formed by B. anthracis protecti ...

    SBIR Phase II 2009 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government